Description: CardioGenics Holdings Inc. is engaged in business of development of products targeting the immunoassay segment of the point-of-care in vitro diagnostic (IVD) testing market. The Company is engaged in development of technology and products, which include The QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic beads. The QLCA is a point-of-care (POC) immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. To support the use of the QLCA, the Company develops approximately four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. Its immunoassay tests include Troponin I (TnI), Plasminogen Activator Inhibitor Type-1 (PAI-1), Heart Failure Risk Stratification (HFRS) and Heart Failure Genomics Risk (HFGR). The Company's TnI test product is in the pilot testing phase. Paramagnetic (magnetic) beads are the solid phase employed during immunoassays tests.
Home Page: www.cardiogenics.com
6295 Northam Drive
Mississauga,
ON
L4V 1W8
Canada
Phone:
905-673-8501
Officers
| Name | Title |
|---|---|
| Dr. Yahia Abdul Gawad | Founder, CEO & Director |
| Mr. James A. Essex CA, MBA | Chief Financial Officer |
| Ms. Linda J. Sterling F.Inst.L.C.O. | Corporate Secretary & Director |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 80069.4287 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 4 |